Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. neocellbank

NeoCellBank

A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 NeoCellBank project word cloud

Explore the words cloud of the NeoCellBank project. It provides you a very rough idea of what is the project "NeoCellBank" about.

individual    age    adult    therapies    good    diseases    lifestyle    mature    veterinary    reverse    rely    tissue    vetbiobank    foresee    overcome    hold    26    incidence    inflammatory    19    lengthy    solution    human    pets    accessible    limited    source    symptoms    context    reaching    stem    amplification    earn    incurring    experiencing    completion    shared    alternative    autologous    neonatal    limits    economic    altered    estimating    hire    commercial    underlying    profits    immunogenicity    osteoarthritis    chronic    15    euros    finalise    disability    inflammation    recipients    expensive    pathology    solutions    endogenous    cells    million    off    abundant    people    therapy    donor    medicine    allogeneic    20    anti    regeneration    profile    disrupt    unrestricted    revolutionize    investment    accelerator    market    humans    mechanism    palliative    ageing    multiple    nsaids    status    introducing    pay    advantages    mostly    joint    society    sedentary    treatments    oa    invasive    burden    mainly    stage    effort    involve    industrialization    appears    biological    animals    regenerative    lower    pharmacological    pro    stronger    cell    material    return   

Project "NeoCellBank" data sheet

The following table provides information about the project.

Coordinator		 VETBIOBANK SAS 

Organization address
address: 1 AVENUE BOURGELAT
city: MARCY-L'ETOILE
postcode: 69280
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website https://www.vetbiobank.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VETBIOBANK SAS FR (MARCY-L'ETOILE) coordinator 50˙000.00

Map

 Project objective

Society is experiencing a rise in chronic inflammatory diseases, mostly due to ageing, and sedentary lifestyle. Osteoarthritis (OA) is one of the leading inflammatory diseases, affecting both humans (incidence 15%) and pets (20%), incurring disability and large economic burden. Current pharmacological treatments for OA involve palliative therapies (NSAIDs) that work on the symptoms, becoming lengthy and expensive with multiple side effects. In this context, regenerative medicine based on stem cells appears as a good alternative, as they reverse the pro-inflammatory status of the joint and promote endogenous tissue regeneration. However, current solutions for OA mainly rely on autologous adult stem cells, obtained through invasive procedures and which hold biological properties altered by donor age and underlying inflammation. Allogeneic adult cells could be used in any individual, but a limited amplification potential limits the number of recipients. In response, we aim to revolutionize the field of regenerative medicine by introducing a unique cell therapy based on neonatal stem cells. These cells have many advantages over adult cells: source material is accessible & abundant, cells show stronger anti-inflammatory properties, and lower immunogenicity profile which allows for unrestricted allogeneic use. The main goal of our project is to finalise industrialization and bring to market our reliable cell-based solution for OA. In Phase 1 we will define the technical and commercial steps to overcome before reaching mature stage. Upon completion of this project, we foresee our product to disrupt the veterinary market of inflammatory diseases. Moreover, since the pathology mechanism for OA is shared between animals and humans, our product could work as an accelerator for human applications. Importantly, the effort will pay off for Vetbiobank, estimating to earn €26 million profits, hire 19 people and reach a Return of Investment of 4.2 Euros after 5 years in the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEOCELLBANK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEOCELLBANK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More  

Woodywood pickering (2019)

Bio-based (fully renewable) cost effective Polymer for new generation of ecological Coatings leveraging a disruptive innovation in the use of Pickering emulsion.

Read More